Introduction
============

Hematopoietic stem cell transplantation (HSCT) is a therapeutic procedure that consists of high-dose chemotherapy followed by an infusion of hematopoietic stem cells (HSCs) derived from harvested bone marrow or peripheral blood, with the objective of restoring hematopoietic system function. There are two types of HSCT, autologous (patients receive their own, previously-harvested HSCs) and allogeneic (patients receive HSCs harvested from a related or unrelated donor). For autologous HSCT, patients receive high-dose chemotherapy and mean time to engraftment and the duration of neutropenia and mucositis may differ from those of allogeneic transplant recipients^([@r01],[@r02])^. For allogeneic HSCT, patients also undergo conditioning regimens that combine high-dose chemotherapy and total body irradiation to induce immunosuppression. Total body irradiation is extremely toxic and leads to severe, protracted mucositis, which is a risk factor for malnutrition, as is the underlying disease^([@r03])^. Graft-versus-host disease (GVHD), which may occur within 10 to 12 days of transplantation, produces more severe complications, particularly in the gastrointestinal tract. High-dose corticosteroid therapy for GVHD management and the use of antiviral drugs to prevent infectious complications also contribute to malnutrition^([@r04],[@r05])^.

Malnutrition is a common issue in oncology patients, and worse clinical outcomes have beenreported in malnourished patients. The goal of nutritional therapy (NT) is to prevent malnutrition secondary to complications and, consequently, prevent worse clinical outcomes^([@r06]-[@r09])^. Although many patients are able to feed orally, intake is often insufficient and requires complementation, whether by enteral feeding (EN) and/or parenteral nutrition (PN). PN is the most widely used alternative, in view of the gastrointestinal problems induced by the clinical complications of induction, radiation, chemotherapy, and other HSCT-related procedures^([@r10])^. However, there is no consensus as to the optimal timing for PN and nutritional requirements (calories per kg of body weight, nonprotein calorie to nitrogen ratio, and grams of protein per kg of body weight) in these patients^([@r06])^.

Given this lack of consensus, there is wide variability in the management of patients with respect to PN. The literature has shown a pressing need for the development and implementationof adequate PN protocols for this patient population with better clinical outcomes having been described in patients enrolled in such protocols^([@r11]-[@r14])^. Due to the difficulty of achieving consensus,there has been little development of nutritional care protocols for patients with cancer as to optimal nutritional therapy, to the variability in current management and to the lack of external validation of management strategies^([@r08],[@r15])^. Current criteria for the prescription of PN range from routine use in all patients with severe malnutrition to prolonged periods (7 to 10 days) of minimal oral intake or significant weight loss (\> 10% of body weight) during treatment^([@r16],[@r19])^.

The effects of nutritional care practices on quality of life, toxicity, and prognosis in cancer patients are still unknown. However, there is evidence to support the assertion that early nutritional supplementation may prevent or decrease the severity of the most common debilitating complications of HSCT^([@r20])^. Therefore, the present study sought to assess the clinical impact of systematic nutritional care on a sample of patients submitted to allogeneic HSCT.

Methods
=======

This double cohort study was carried out on a sample of adult patients (age \>18 years) undergoing allogeneic HSCT. Two groups of patients were formed relating to two assessment periods: from April 2003 to April 2004, which constituted the Non-intervention Group (NIG), and from March 2006 to January 2008, which constituted the Intervention Group (IG). The intervention evaluated in this study, systematic nutritional care for HSCT patients, was implemented in 2005; therefore, patients admitted over the course of this year were not included in the study, as this was atransitional period for adaptation. All patients were enrolled only once, at the time of HSCT. Patients admitted for retransplantation or management of HSCT complications were not included.

The NIG was constructed retrospectively through analysis ofthe database of the Department of Hematology at the Hospital de Clínicas de Porto Alegre (HCPA), Brazil, where the study was carriedout. In 2005, the HCPA Physician Nutrition Specialist Service, Nutrition and Dietetics Service and Department of Hematology jointly developed and implemented a protocol of routine, systematic nutritional care for all adult HSCT patients ([Figure 1](#F1){ref-type="fig"}).
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The IG was assessed prospectively for the same variables analyzed in the NIG, as described below. IG follow-up was led by the medical and nutritional teams of the HSCT unit. No changes were made in the type of diet or supplemental nutrition provided between the pre-intervention and post-intervention periods, but criteria for institution and discontinuation of PN, according to oral intake, were established. Clinical and nutritional parameters were assessed by meansof a standard protocol, which was used in both groups. Nutritional assessment was carried out by a staff dietitian in the HSCT unit or by a previously trained student dietitian on admission and throughout the hospital stay. Body mass index (BMI), mid-upper arm circumference (MUAC), triceps skinfold thickness (TSF), and percent weight loss (%WL) were assessed. Weight was measured at the HSCT unit usingdigital scales with stadiometer (OS 180 A®, Urano). MUAC wasmeasured with a flexible, non-stretch anthropometric measuring tape (Barlow®) and TSF, with a skinfold caliper (Cescorf®), in accordance with World Health Organization (WHO) recommendations. BMI, %WL and MUAC were calculated as per WHO recommendations^([@r19])^.

Mortality, infection, and prolonged hospital stay were considered dependent variables. Hospital-acquired infection was defined as any infection that developed during hospitalization, regardless of site of origin, in accordance with the local Hospital-Acquired Infection Control Committee (HAICC) protocols. Prolonged length of stay was defined as any hospitalization exceeding the mean length expected for HSCT recipients, i.e. 56 days.

Statistical analysis
--------------------

Study variables were analyzed in the SPSS 17.0. software environment. The Shapiro-Wilk test was used to determine normality and variables were then expressed as means and standard deviations or medians and ranges depending on their distribution. Relative frequencies (percentages) were also used in describing the sample. Significance was set for a p-value \< 0.05.

Results
=======

The NIG (pre-implementation of the study intervention, 2002-2004) comprised 57 patients whereas the IG (post-implementation, 2006-2008) comprised 34 patients. [Table 1](#T1){ref-type="table"} shows the distribution of hematological diseases of patients in each of the study groups.

###### 

Distribution of indications for hematopoietic stem cell transplantation in the Non-intervention and Intervention Groups

  **Disease**                                     **NIG**     **NIG**
  ----------------------------------------------- ----------- ----------
  Aplastic anemia                                 5 (8.8)     4 (11.7)
  Myelodysplasia                                  3 (5.3)     7 (20.6)
  Hodgkin\'s disease                              2 (3.5)     2 (5.9)
  Leukemia, acute biphenotypic or lymphoblastic   8 (14.1)    3 (8.8)
  Leukemia, chronic lymphocytic                   2 (3.5)     0
  Leukemia, acute myeloid                         14 (24.6)   9 (26.5)
  Leukemia, chronic myeloid                       15 (26.3)   6 (17.7)
  Lymphoma, T-cell                                2 (3.5)     0
  Lymphoma, non-Hodgkin                           4 (7.02)    3 (8.8)
  Multiple myeloma                                2 (3.5)     0

[Table 2](#T2){ref-type="table"} shows the demographic profile of the two groups and the distribution of graft type and conditioning regimen.

###### 

Median age, gender, distribution, graft type and conditioning regimen for the Non-intervention and Intervention Groups

  ---------------------------------------- ------------ ------------ -------------
                                           **NIG**      **IG**       **p-value**
  Age (years) - median (range)             37 (19-55)   35 (19-60)   0.249
  Females - n (%)                          35 (61.4)    14 (41.2)    0.063
  Males - n (%)                            22 (38.6)    20 (58.8)     
  Related-donor - n (%)                    57 (100)     25 (73.5)    0.000
  Unrelated-donor - n (%)                  0            9 (26.5)      
  Myeloablative conditioning - n (%)       43 (75.4)    27 (79.4)    0.665
  Non-myeloablative conditioning - n (%)   14 (24.6)    7 (20.6)      
  ---------------------------------------- ------------ ------------ -------------

Anthropometric assessment showed no significant pre-hospitalization weight loss in either group. Mean weight loss was 0.83% (range: -1.48 to 4.8%) in the NIG and 0.14% (range: -3.8 to 4.8%) in the IG. Mean BMI was 25.28 kg/m^2^ (range: 22.65 to 28.03 kg/m^2^) in the NIG and 24.89 kg/m^2^ (range: 21.95 to 28.82 kg/m^2^) in the IG^([@r21])^. There were no significant differences between groups in respect to anthropometric parameters (DCT, CB and CMB) on admission.

PN was prescribed to 30 (52.6%) patients in the NIG and 20 patients (58.8%) in the IG. The duration of PN, mean PN calorie intake and mean oral calorie intake are shown in [Table 3](#T3){ref-type="table"}.

###### 

Comparison between duration of parenteral nutrition and mean caloric intake in the Non-intervention and Intervention Groups

                                                                  **Non-intervention Group**   **Intervention Group**                                                         
  --------------------------------------------------------------- ---------------------------- ------------------------ -------------- ------------ ------------ ------------ ----------
  Patients receiving PN - n (%)                                   30 (52.6)                    26 (61.9)                4 (26.6)       14 (56)      6 (66.6)     20 (71.4)    0
  Duration of PN (days) - median (range)                          20.5 (4-73)                  20.5 (4-73)              18.5 (11-59)   6.5 (1-28)   11 (1-21)    7 (1-28)     0
  Daily PN calorie intake (kcal) - Mean ± SD                      1554 ± 309                   1600 ± 259               1395 ± 425     1516 ±250    1343 ± 462   1480 ± 299   0
  Mean daily oral intake during oral feeding (kcal) - Mean ± SD   1310 ± 465                   1288 ± 446               1366 ± 525     1642 ± 586   1646 ± 598   1609 ± 616   1801±366

PN: parenteral nutrition; SD; Standard deviation

There were no significant differences between related-donor and unrelated-donor graft recipients with respect to any of the outcomes of interest ([Table 4](#T4){ref-type="table"}).

###### 

Comparison between main outcomes by group (Non-intervention vs. Intervention Group): graft type, and conditioning regimen

                                                 **Non-intervention Group**   **Intervention Group**                                                            
  ---------------------------------------------- ---------------------------- ------------------------ ------------- ------------ ------------- --------------- ------------
  Hospital stay (days) - median (range)          43 (15-101)                  43 (15-93)               41 (28-101)   41 (23-89)   48 (24-117)   42.5 (23-117)   36 (24-78)
  Infections - n (%)                             39 (68.4)                    25 (59.5)                14 (93.3)     17 (68)      5 (55.5)      18 (64.3)       4 (6.66)
  In-hospital deaths - n (%)                     9 (15.8)                     9 (15.8)                 0             5 (20)       5 (55.5)      7 (25)          1 (16.6)
  Death at 6 months - n (%)                      14 (24.6)                    12 (28.6)                2 (13.3)      8 (32)       3 (33.3)      10 (35.7)       1 (16.6)
  Death at 12 months - n (%)                     29 (50.9)                    22 (52.4)                7 (4.6)       7 (28)       3 (33.3)      10 (35.7)       0
  Number post-HSCT admissions - median (range)   2 (0-16)                     2 (0-16)                 2(0-15)       3 (1-14)     7 (0-14)      5 (1-14)        2.5 (0-12)
  **Chronic GVHD - n (%)**                                                                                                                                       
      None                                       34 (59.65)                   29 (69)                  5 (33.3)      20 (80)      9 (100)       24 (85.7)       5 (83.3)
      Limited                                    13 (22.8)                    8 (19)                   5 (33.3)      4 (16)       0             4 (14.3)        0
      Extensive                                  10 (17.5)                    5 (11.9)                 5 (33.3)      1 (4)        0             0               1 (16.6)
  **Acute GVHD - n (%)**                                                                                                                                         
      Grade I/II                                 14 (24.6)                    8 (19)                   6 (40)        9 (36)       3 (33.3)      10 (35.7)       2 (33.3)
      Grade III/IV                               10 (17.5)                    7 (16.6)                 3 (20)        3 (12)       1 (11.1)      3 (10.7)        1 (16.6)
  CMV - n (%)                                    10 (17.5)                    8 (19)                   2 (13.3)      7 (28)       4 (44.4)      8 (28.6)        3 (50)
  In-hospital weight loss \> 10% - n (%)         22 (38.6)                    14 (33.3)                8 (53.3)      10 (40)      5 (55.5)      12 42.8)        3 (50)
  Neutropenia - n (%)                            55 (96.5)                    41 (97.6)                14 (93.3)     20 (80)      8 (88.8)      22 (78.5)       6 (100)

HSCT: Hematopoietic stem cell transplantation; GVHD: Graft versus host disease; CMV: Cytomegalovirus

There were no significant differences between groups in length of hospital stay, prolonged hospitalization rate, presence and severity of GVHD, infection rate, or duration of neutropenia.

There were no significant differences between groups in inhospital death or post-transplant mortality at 6 months or 12 months.

Discussion
==========

Nutritional and clinical assessment revealed no significant differences between groups for any of the variables of interest, confirming the similarity in nutritional and clinical profile of the study sample prior to the intervention.

Less PN was given to patients in the IG than those in the NIG; however, as both groups were similar at the time of HSCT, this means that prescription of PN was optimized in the IG. This rationalization of management after the implementation of a nutritional care protocol will certainly have reduced hospital costs.

There were no significant differences in the post-HSCT complication rates, infection rates or lengths of hospital stay. This may be explained by the fact that length of stay is determined by the duration of treatment itself, that the mortality rate may have been the same due to universally adequate treatment and that PN-associated infection rates are mostly determined by care in compounding^([@r22])^.

In the present study, 52% of patients in the NIG and 58% of those in the IG received PN. This is within the range reported in the literature, where the percentage of HSCT patients given PN ranges from 37% in autologous graft recipients to 91% in unrelated-donor allogeneic graft recipients^([@r16])^.

The duration of PN may have an impact on catheter-related infection rates and on hospitalization costs. In the literature, the mean duration of PN after HSCT ranges from 6.9-16 days after autologous transplantation and 10.3-25 days after allogeneic ransplantation^([@r15],[@r16],[@r23])^. The present study showed a reduction in PN duration in the IG. Use of a nutritional care protocol, including control and optimization of food intake, in these patients may reduce the duration of PN by approximately 14 days in patients undergoing related-donor allogeneic HSCT. We found in this work a median duration of PN of 6.5 days (range: 1-28) in related-donorgraft recipients and 11 days (range: 1-21) in unrelated-donor graft recipients. This duration is well short of that usually reported in the literature for allogeneic HSCT recipients. Although other factors associated with better care in these patients (such as better use of antiemetics and prophylaxis for GVHD) may have had an impact, monitoring of dietary intake plays an essential role in determining when to discontinue parenteral nutrition^([@r16])^.

We believe PN should not be used routinely as first-line therapy, but rather restricted to patients who are unable to tolerate enteral feeding and will derive real benefit from PN^([@r24])^.

HSCT patients who receive PN, when indicated, may experience fewer complications when adequate nutritional supportis provided^([@r13],[@r25])^. Furthermore, the lack of adequate nutritional support may lead to increased complication rates and prolong hospitalization, consequently leading to higher hospital costs^([@r14],[@r23])^.

Conclusion
==========

The implementation of a systematic nutritional follow-up and therapy protocol for adult patients undergoing allogeneic hematopoietic stem cell transplantation optimized (shortened) the duration of parenteral nutrition.
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